GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (STU:DUL) » Definitions » Cyclically Adjusted Price-to-FCF

Alnylam Pharmaceuticals (STU:DUL) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alnylam Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Alnylam Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alnylam Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alnylam Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Alnylam Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Alnylam Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Alnylam Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.689/131.7762*131.7762
=-0.689

Current CPI (Mar. 2024) = 131.7762.

Alnylam Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.470 100.560 -0.616
201409 -0.446 100.428 -0.585
201412 -0.423 99.070 -0.563
201503 -0.319 99.621 -0.422
201506 -0.599 100.684 -0.784
201509 -0.641 100.392 -0.841
201512 -0.607 99.792 -0.802
201603 -1.005 100.470 -1.318
201606 -0.861 101.688 -1.116
201609 -0.996 101.861 -1.289
201612 -1.085 101.863 -1.404
201703 -1.483 102.862 -1.900
201706 -1.038 103.349 -1.324
201709 -1.133 104.136 -1.434
201712 -1.087 104.011 -1.377
201803 -1.435 105.290 -1.796
201806 -1.068 106.317 -1.324
201809 -1.694 106.507 -2.096
201812 -1.635 105.998 -2.033
201903 -1.953 107.251 -2.400
201906 2.180 108.070 2.658
201909 -1.827 108.329 -2.222
201912 -1.890 108.420 -2.297
202003 -2.133 108.902 -2.581
202006 -1.175 108.767 -1.424
202009 -0.898 109.815 -1.078
202012 -1.022 109.897 -1.225
202103 -1.814 111.754 -2.139
202106 -0.938 114.631 -1.078
202109 -1.142 115.734 -1.300
202112 -1.271 117.630 -1.424
202203 -1.426 121.301 -1.549
202206 -1.087 125.017 -1.146
202209 -1.090 125.227 -1.147
202212 -1.176 125.222 -1.238
202303 -1.357 127.348 -1.404
202306 -0.555 128.729 -0.568
202309 2.442 129.860 2.478
202312 -0.329 129.419 -0.335
202403 -0.689 131.776 -0.689

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alnylam Pharmaceuticals  (STU:DUL) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Alnylam Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (STU:DUL) Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (STU:DUL) Headlines

No Headlines